Douglas R. Carlson
Director of Finance/CFO chez Avenge Bio, Inc.
Profil
Douglas R.
Carlson is currently the Chief Operating & Financial Officer at Avenge Bio, Inc. He previously worked as a Senior Director-Business Development at BTG International, Inc., Director-Corporate Development at OVATION Pharmaceuticals, Inc., Senior Director & Head-Business Development at Lundbeck, Inc., Analyst at Cowen & Co. LLC, Vice President-Business Development at Collegium Pharmaceutical, Inc., and Associate at FirstMark Capital LLC.
Carlson also served as the Chief Operating Officer & Executive VP-Finance at Ikena Oncology, Inc. from 2019 to 2022.
He received his undergraduate degree from Trinity College (Connecticut) in 2001.
Postes actifs de Douglas R. Carlson
| Sociétés | Poste | Début |
|---|---|---|
Avenge Bio, Inc.
 Avenge Bio, Inc. Pharmaceuticals: MajorHealth Technology Avenge Bio, Inc. is an oncology-focused biotechnology company based in the United States. The American company develops cell-based immunotherapeutic products for the treatment of solid tumors using its proprietary Lococyte™ platform. The platform delivers engineered cells to the local tumor environment, generating high concentrations of immune effector molecules in proximity to the tumor, which initiates a robust, local, and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. The company has additional pipeline candidates for the treatment of a wide range of cancers, including pancreatic, lung, and breast cancers. Avenge was founded in 2019 by Paul Kevin Wotton and Michael Thomas Heffernan, with Heffernan serving as CEO since incorporation. | Director of Finance/CFO | 22/02/2022 |
Anciens postes connus de Douglas R. Carlson
| Sociétés | Poste | Fin |
|---|---|---|
| IKENA ONCOLOGY, INC. | Director of Finance/CFO | 18/02/2022 |
Lundbeck, Inc.
 Lundbeck, Inc. Pharmaceuticals: MajorHealth Technology Part of Lundbeck Foundation, Lundbeck, Inc. is a pharmaceutical company that produces pharmaceutical preparations. The private company is based in Paramus, NJ. The company was founded by Jeffrey S. Aronin. | Corporate Officer/Principal | 01/08/2011 |
FirstMark Capital LLC
 FirstMark Capital LLC Investment ManagersFinance FirstMark Capital LLC (FirstMark Capital) is venture capital firm founded by Rick Heitzmann and Amish Jani in 1996. The firm is headquartered in New York. | Private Equity Analyst | 31/12/2006 |
OVATION Pharmaceuticals, Inc.
 OVATION Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OVATION Pharmaceuticals, Inc. develops, manufactures and markets pharmaceuticals. It focuses on central nervous system, hematology or oncology and hospital-based therapies. The company was founded by Jeffrey S. Aronin in 2000 and is headquartered in Deerfield, IL. | Corporate Officer/Principal | - |
BTG International, Inc.
 BTG International, Inc. Investment ManagersFinance BTG International Inc. (BTG International) is a venture capital subsidiary of BTG Ltd founded in 1981. The firm is headquartered in West Conshohocken, Pennsylvania. | Corporate Officer/Principal | - |
Formation de Douglas R. Carlson
| Trinity College (Connecticut) | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| COLLEGIUM PHARMACEUTICAL, INC. | Health Technology |
| IKENA ONCOLOGY, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Cowen & Co. LLC
 Cowen & Co. LLC Investment Banks/BrokersFinance Cowen & Co. LLC is a SEC-registered broker/dealer headquartered in New York City. The firm was founded in 2004 and is a subsidiary of Cowen Holdings, Inc., ultimately owned by The Toronto-Dominion Bank (TSE: TD) in Canada. Cowen & Co. offers industry-focused investment banking for growth-oriented companies, domain knowledge-driven research and a sales and trading platform for institutional investors. Their institutional sales and trading business serves both equity and fixed-income clients. Sales and trading execution platform is structured around the following key verticals: (1) healthcare (2) technology, telecommunications and media (TMT) (3) REITs and financials (4) aerospace and defense (5) consumer and (6) alternative energy. | Finance |
FirstMark Capital LLC
FirstMark Capital LLC Investment ManagersFinance FirstMark Capital LLC (FirstMark Capital) is venture capital firm founded by Rick Heitzmann and Amish Jani in 1996. The firm is headquartered in New York. | Finance |
BTG International, Inc.
BTG International, Inc. Investment ManagersFinance BTG International Inc. (BTG International) is a venture capital subsidiary of BTG Ltd founded in 1981. The firm is headquartered in West Conshohocken, Pennsylvania. | Finance |
OVATION Pharmaceuticals, Inc.
OVATION Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OVATION Pharmaceuticals, Inc. develops, manufactures and markets pharmaceuticals. It focuses on central nervous system, hematology or oncology and hospital-based therapies. The company was founded by Jeffrey S. Aronin in 2000 and is headquartered in Deerfield, IL. | Health Technology |
Lundbeck, Inc.
Lundbeck, Inc. Pharmaceuticals: MajorHealth Technology Part of Lundbeck Foundation, Lundbeck, Inc. is a pharmaceutical company that produces pharmaceutical preparations. The private company is based in Paramus, NJ. The company was founded by Jeffrey S. Aronin. | Health Technology |
Avenge Bio, Inc.
Avenge Bio, Inc. Pharmaceuticals: MajorHealth Technology Avenge Bio, Inc. is an oncology-focused biotechnology company based in the United States. The American company develops cell-based immunotherapeutic products for the treatment of solid tumors using its proprietary Lococyte™ platform. The platform delivers engineered cells to the local tumor environment, generating high concentrations of immune effector molecules in proximity to the tumor, which initiates a robust, local, and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. The company has additional pipeline candidates for the treatment of a wide range of cancers, including pancreatic, lung, and breast cancers. Avenge was founded in 2019 by Paul Kevin Wotton and Michael Thomas Heffernan, with Heffernan serving as CEO since incorporation. | Health Technology |
